Skip to content
Open access · US-GOV via ClinicalTrials.gov Clinical trial

A Phase IIa Study of Allogeneic Human Mesenchymal Stem Cells in Subjects With Mild to Moderate Dementia Due to Alzheimer's Disease

Authors not listed

Stemedica Cell Technologies, Inc. · 2016

Abstract

STUDY OBJECTIVES Primary: To assess the safety and tolerability of ischemia-tolerant allogeneic human mesenchymal stem cells (hMSCs) manufactured by Stemedica versus placebo administered intravenously to subjects with mild to moderate dementia due to Alzheimer's disease. Secondary: To assess the preliminary efficacy of hMSCs versus placebo in subjects with Alzheimer's-related dementia, as evidenced by neurologic, functional, and psychiatric endpoints.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
ClinicalTrials.gov
Canonical
link ↗
Fetched
2026-11-08 MST

Cite this

APA
Anonymous. (2016). A Phase IIa Study of Allogeneic Human Mesenchymal Stem Cells in Subjects With Mild to Moderate Dementia Due to Alzheimer's Disease. <em>Stemedica Cell Technologies, Inc.</em>. https://clinicaltrials.gov/study/NCT02833792
Vancouver
Anonymous. A Phase IIa Study of Allogeneic Human Mesenchymal Stem Cells in Subjects With Mild to Moderate Dementia Due to Alzheimer's Disease. Stemedica Cell Technologies, Inc.. 2016.
BibTeX
@misc{anon2016APhase, title = {A Phase IIa Study of Allogeneic Human Mesenchymal Stem Cells in Subjects With Mild to Moderate Dementia Due to Alzheimer's Disease}, author = {Anonymous}, journal = {Stemedica Cell Technologies, Inc.}, year = {2016}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings